ArticleScientific reports2026
Hot melt extruded Kyungohkgo attenuates skeletal muscle atrophy by downregulating the FOXO3a/MuRF-1/atrogin-1 axis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanotechnological Strategies to Promote Skeletal Muscle Regeneration in Aging.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Skeletal muscle atrophy is a common and debilitating consequence of chronic diseases and aging, yet effective treatment alternatives remain limited. Kyungohkgo (KOG), a traditional oriental medicine, has been shown to have potential therapeutic benefits for muscle health, but its therapeutic efficacy is restricted caused by poor bioavailability. This study aimed to enhance both the bioavailability and efficacy of KOG by applying hot-melt extrusion (HME) processing, creating a modified formulation to evaluate its effectiveness in treating skeletal muscle atrophy. Network pharmacology analysis was conducted to illustrate the relationships between the traditional medicine KOG and sarcopenia. Both in vivo and in vitro models of skeletal muscle atrophy were employed to compare the effects of conventional KOG and HME-processed KOG (HOG3). HME processing yielded an optimized formulation, HOG3, characterized by nanoscale particle size and a marked increase in minor ginsenoside content. In this study, HOG3 showed significantly higher ginsenoside levels than KOG, with Rg3, compound K, and Rh2 increasing approximately 19-, 78-, and 18-fold, respectively. In cellular and animal models, HOG3 outperformed KOG in preserving muscle mass, reducing muscle degradation markers, and decreasing collagen deposition. HOG3 administration was associated with decreased expression level of FOXO3a, MuRF-1, and atrogin-1. Overall, these findings show that HOG3 indicates enhanced protective effects against skeletal muscle atrophy and is associated with modulation of downstream molecular markers related to muscle degradation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.